In its continued bid to waylay the launch of MSN Pharmaceuticals’ proposed Entresto generic, Novartis has told a federal ...

Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate ...

Novartis admitted the email broke several rules set out in the U.K. marketing code. In a long response to the PMCPA, the ...

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.

Detailed data will be presented at a future medical meeting and submitted for regulatory review later this year.

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Regulus filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC, which includes, among other things, the recommendation of Regulus’s board of directors that Regulus’s stockholders ...

Novartis introduces a financing scheme with Pine Labs for its cholesterol-lowering drug, Sybrava (inclisiran), in India, ...

Loomis Sayles, an investment management company, released its “Global Growth Fund” first quarter 2025 investor letter. A copy ...

Seven pharmaceutical giants with a presence in New Jersey have announced billions in expansions. The timing is no surprise, health care analysts say.

Regulus Therapeutics Inc.‘s up to $1.7 billion sale to Novartis AG was flawed, primarily benefiting board members and executives who have large amounts of illiquid shares instead of public ...